As adeno-associated viral vector (AAV) manufacturing has evolved from research-scale production to commercial operations, controlling capsid content is no longer a downstream “nice-to-have”; instead, it’s a primary determinant of manufacturability, safety, and therapeutic effect. That mandate raises a critical question: how accurately can developers quantify the particles their processes produce?
Now more than ever, developers are relying on orthogonal techniques, cross-confirming results, increasing confidence in data, and building the historical comparability frameworks required for regulatory acceptance. In short, they’re selecting the right toolbox and combining techniques intelligently to ensure that every dose delivered to a patient is as controlled, predictable, and potent as intended.
Learn more in our whitepaper: “The Problem of Partials: Redefining the Analytical Frameworks Surrounding Capsid Characterization.”